These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
349 related articles for article (PubMed ID: 30595538)
1. SPOP Promotes Nanog Destruction to Suppress Stem Cell Traits and Prostate Cancer Progression. Zhang J; Chen M; Zhu Y; Dai X; Dang F; Ren J; Ren S; Shulga YV; Beca F; Gan W; Wu F; Lin YM; Zhou X; DeCaprio JA; Beck AH; Lu KP; Huang J; Zhao C; Sun Y; Gao X; Pandolfi PP; Wei W Dev Cell; 2019 Feb; 48(3):329-344.e5. PubMed ID: 30595538 [TBL] [Abstract][Full Text] [Related]
2. AMPK Promotes SPOP-Mediated NANOG Degradation to Regulate Prostate Cancer Cell Stemness. Wang X; Jin J; Wan F; Zhao L; Chu H; Chen C; Liao G; Liu J; Yu Y; Teng H; Fang L; Jiang C; Pan W; Xie X; Li J; Lu X; Jiang X; Ge X; Ye D; Wang P Dev Cell; 2019 Feb; 48(3):345-360.e7. PubMed ID: 30595535 [TBL] [Abstract][Full Text] [Related]
3. Prostate cancer-associated mutation in SPOP impairs its ability to target Cdc20 for poly-ubiquitination and degradation. Wu F; Dai X; Gan W; Wan L; Li M; Mitsiades N; Wei W; Ding Q; Zhang J Cancer Lett; 2017 Jan; 385():207-214. PubMed ID: 27780719 [TBL] [Abstract][Full Text] [Related]
4. SPOP Promotes Ubiquitination and Degradation of the ERG Oncoprotein to Suppress Prostate Cancer Progression. Gan W; Dai X; Lunardi A; Li Z; Inuzuka H; Liu P; Varmeh S; Zhang J; Cheng L; Sun Y; Asara JM; Beck AH; Huang J; Pandolfi PP; Wei W Mol Cell; 2015 Sep; 59(6):917-30. PubMed ID: 26344095 [TBL] [Abstract][Full Text] [Related]
5. Cullin 3SPOP ubiquitin E3 ligase promotes the poly-ubiquitination and degradation of HDAC6. Tan Y; Ci Y; Dai X; Wu F; Guo J; Liu D; North BJ; Huo J; Zhang J Oncotarget; 2017 Jul; 8(29):47890-47901. PubMed ID: 28599312 [TBL] [Abstract][Full Text] [Related]
6. Destruction of DDIT3/CHOP protein by wild-type SPOP but not prostate cancer-associated mutants. Zhang P; Gao K; Tang Y; Jin X; An J; Yu H; Wang H; Zhang Y; Wang D; Huang H; Yu L; Wang C Hum Mutat; 2014 Sep; 35(9):1142-51. PubMed ID: 24990631 [TBL] [Abstract][Full Text] [Related]
7. SPOP suppresses pancreatic cancer progression by promoting the degradation of NANOG. Tan P; Xu Y; Du Y; Wu L; Guo B; Huang S; Zhu J; Li B; Lin F; Yao L Cell Death Dis; 2019 Oct; 10(11):794. PubMed ID: 31624231 [TBL] [Abstract][Full Text] [Related]
8. SPOP promotes ubiquitination and degradation of LATS1 to enhance kidney cancer progression. Wang L; Lin M; Chu M; Liu Y; Ma J; He Y; Wang ZW EBioMedicine; 2020 Jun; 56():102795. PubMed ID: 32460168 [TBL] [Abstract][Full Text] [Related]
9. ERK1/2 inhibits Cullin 3/SPOP-mediated PrLZ ubiquitination and degradation to modulate prostate cancer progression. Fan Y; Hou T; Dan W; Zhu Y; Liu B; Wei Y; Wang Z; Gao Y; Zeng J; Li L Cell Death Differ; 2022 Aug; 29(8):1611-1624. PubMed ID: 35194188 [TBL] [Abstract][Full Text] [Related]
10. Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. Dai X; Gan W; Li X; Wang S; Zhang W; Huang L; Liu S; Zhong Q; Guo J; Zhang J; Chen T; Shimizu K; Beca F; Blattner M; Vasudevan D; Buckley DL; Qi J; Buser L; Liu P; Inuzuka H; Beck AH; Wang L; Wild PJ; Garraway LA; Rubin MA; Barbieri CE; Wong KK; Muthuswamy SK; Huang J; Chen Y; Bradner JE; Wei W Nat Med; 2017 Sep; 23(9):1063-1071. PubMed ID: 28805820 [TBL] [Abstract][Full Text] [Related]
11. SPOP promotes CDCA5 degradation to regulate prostate cancer progression via the AKT pathway. Luo Z; Wang J; Zhu Y; Sun X; He C; Cai M; Ma J; Wang Y; Han S Neoplasia; 2021 Oct; 23(10):1037-1047. PubMed ID: 34509929 [TBL] [Abstract][Full Text] [Related]
12. Mutated SPOP E3 Ligase Promotes 17βHSD4 Protein Degradation to Drive Androgenesis and Prostate Cancer Progression. Shi L; Yan Y; He Y; Yan B; Pan Y; Orme JJ; Zhang J; Xu W; Pang J; Huang H Cancer Res; 2021 Jul; 81(13):3593-3606. PubMed ID: 33762355 [TBL] [Abstract][Full Text] [Related]
13. SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of c-MYC oncoprotein. Geng C; Kaochar S; Li M; Rajapakshe K; Fiskus W; Dong J; Foley C; Dong B; Zhang L; Kwon OJ; Shah SS; Bolaki M; Xin L; Ittmann M; O'Malley BW; Coarfa C; Mitsiades N Oncogene; 2017 Aug; 36(33):4767-4777. PubMed ID: 28414305 [TBL] [Abstract][Full Text] [Related]
14. SPOP promotes ATF2 ubiquitination and degradation to suppress prostate cancer progression. Ma J; Chang K; Peng J; Shi Q; Gan H; Gao K; Feng K; Xu F; Zhang H; Dai B; Zhu Y; Shi G; Shen Y; Zhu Y; Qin X; Li Y; Zhang P; Ye D; Wang C J Exp Clin Cancer Res; 2018 Jul; 37(1):145. PubMed ID: 29996942 [TBL] [Abstract][Full Text] [Related]
15. Deficiency in SPOP-mediated ubiquitination and degradation of TIAM1 promotes gastric cancer progression. Liu F; Zhang T; Sun X; Liu Z; Xu W; Dai X; Zhang X Biochim Biophys Acta Mol Basis Dis; 2024 Mar; 1870(3):167032. PubMed ID: 38246227 [TBL] [Abstract][Full Text] [Related]
16. Snail promotes prostate cancer migration by facilitating SPOP ubiquitination and degradation. Lv W; Huan M; Yang W; Gao Y; Wang K; Xu S; Zhang M; Ma J; Wang X; Chen Y; Li L Biochem Biophys Res Commun; 2020 Aug; 529(3):799-804. PubMed ID: 32736710 [TBL] [Abstract][Full Text] [Related]
17. Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. Janouskova H; El Tekle G; Bellini E; Udeshi ND; Rinaldi A; Ulbricht A; Bernasocchi T; Civenni G; Losa M; Svinkina T; Bielski CM; Kryukov GV; Cascione L; Napoli S; Enchev RI; Mutch DG; Carney ME; Berchuck A; Winterhoff BJN; Broaddus RR; Schraml P; Moch H; Bertoni F; Catapano CV; Peter M; Carr SA; Garraway LA; Wild PJ; Theurillat JP Nat Med; 2017 Sep; 23(9):1046-1054. PubMed ID: 28805821 [TBL] [Abstract][Full Text] [Related]
18. Dysregulation of INF2-mediated mitochondrial fission in SPOP-mutated prostate cancer. Jin X; Wang J; Gao K; Zhang P; Yao L; Tang Y; Tang L; Ma J; Xiao J; Zhang E; Zhu J; Zhang B; Zhao SM; Li Y; Ren S; Huang H; Yu L; Wang C PLoS Genet; 2017 Apr; 13(4):e1006748. PubMed ID: 28448495 [TBL] [Abstract][Full Text] [Related]
19. Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation. Zhang P; Wang D; Zhao Y; Ren S; Gao K; Ye Z; Wang S; Pan CW; Zhu Y; Yan Y; Yang Y; Wu D; He Y; Zhang J; Lu D; Liu X; Yu L; Zhao S; Li Y; Lin D; Wang Y; Wang L; Chen Y; Sun Y; Wang C; Huang H Nat Med; 2017 Sep; 23(9):1055-1062. PubMed ID: 28805822 [TBL] [Abstract][Full Text] [Related]
20. SPOP-mediated degradation of BRD4 dictates cellular sensitivity to BET inhibitors. Dai X; Wang Z; Wei W Cell Cycle; 2017; 16(24):2326-2329. PubMed ID: 29108467 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]